This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) injection, for subcutaneous use, is a HER2/neu receptor antagonist.
It is indicated for use in combination with chemotherapy as neoadjuvant treatment (this is the treatment given as a first step) of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer, adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, and in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
If a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phesgo, please immediately report pregnancy to the local Roche Adverse Event Line at
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
Solutions